Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Authors:
- 25 November 2021
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 31 (6) , 549-555
Abstract
Immune checkpoint inhibitors (ICIs) have recently entered into the therapeutic scenario of metastatic breast cancer. However, only a proportion of patients benefit from ICIs and immune-based combin...Keywords
This publication has 85 references indexed in Scilit:
- Breast Cancer Immunotherapy: Facts and HopesClinical Cancer Research, 2018
- Classification and characterization of microsatellite instability across 18 cancer typesNature Medicine, 2016
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- Microsatellite Instability as a Biomarker for PD-1 BlockadeClinical Cancer Research, 2016
- Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapyPathology, 2016
- A Breakthrough: Macrophage-Directed Cancer ImmunotherapyCancer Research, 2016
- Targeting the DNA Damage Response in CancerMolecular Cell, 2015
- Cancer immunotherapy: harnessing the immune system to battle cancerJournal of Clinical Investigation, 2015
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012